Loading stock data…
STIM
$2.02+0.08 (+4.12%)
After Hours$2.00-0.02 (-0.99%)· Last close May 1
Neuronetics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neuronetics, Inc. in the Healthcare sector is trading at $2.02. The stock is currently 58% below its 52-week high of $4.85, remaining 11.0% below its 200-day moving average. Technical signals show overbought RSI of 82 and bullish MACD crossover, explaining why STIM maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 82) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.02
Potential Upside
5%
Whystock Fair Value$2.12
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatme...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$117.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.87
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-218.06%
Volume
Today's trading volume
3.85M
Recent News
How The Neuronetics (STIM) Investment Story Is Reset As Analysts Rework Valuation Assumptions
Neuronetics’ latest analyst update keeps the fair value price target unchanged at US$4.33, signaling that the core valuation view is intact for now. Bullish and bearish analysts are reading that steady figure very differently, using it to support opposing views on risk, sentiment, and how expectations for the stock are being reset. As you read on, you will see how to track these shifting narratives and what they might mean for your own research on Neuronetics. Stay updated as the Fair Value...
How The Neuronetics (STIM) Story Is Shifting As Analysts Rework Valuation Assumptions
Neuronetics is back in focus as analysts revisit their models and what that means for the stock’s fair value, with the updated fair value still set at $4.33. The latest commentary centers on how this unchanged price target fits with investor expectations, given the detailed discussion around required returns and what investors may be willing to pay today. Read on to see how to track these shifts in the story and keep up with the evolving analyst narrative around Neuronetics. Analyst Price...
Neuronetics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Neuronetics, Inc.'s Q4 2025 earnings call
Neuronetics (STIM) Q4 2025 Earnings Transcript
Before we begin, I would like to caution listeners that certain information discussed by management during this conference call will include forward-looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to our business, strategy, financial and revenue guidance, the Greenbrook integration, and other operational issues and metrics. Actual results can differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business.
Neuronetics Q4 Earnings Call Highlights
Neuronetics (NASDAQ:STIM) reported fourth-quarter 2025 financial and operating results highlighted by its first full year operating with the Greenbrook clinic network, strong adjusted pro forma revenue growth, and positive operating cash flow in the quarter. Management also announced a leadership tr